Transparency Market Research

Human Reproductive Technologies Market Will Reach US$27.1 Billion by 2019

Transparency Market Research Report Added "Human Reproductive Technologies Market" to its database.


Albany, NY -- (SBWIRE) -- 02/24/2015 -- Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019

In the new report published by Transparency Market Research "Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019," the global human reproductive market technologies was worth US$23.0 billion in 2012. However, according to some recent research and statistics the overall human reproductive technologies market is growing at a CAGR 2.2% from 2013 to 2019 and is expected to reach US$27.1 billion in 2019.

Browse the full report at

In order to provide a thorough analysis of the overall competitive scenario in the global human reproductive technologies market, this report covers every aspect of the market and analyzes it in terms of treatment technologies, drugs, and various devices that are used to assist and control human reproduction.
Considering the human reproductive technologies market on the basis of market segmentation, the global market is divided into two major segments: contraceptive technologies and infertility treatments. The report involves the study of several providers and manufacturers of contraceptive technologies and infertility solutions too.

The contraceptive technologies market is further classified into contraceptive devices and drugs. The contraceptive devices market is sectioned into female contraceptive devices and male contraceptive devices (condoms), while, the contraceptive drugs market comprises topical contraceptives, contraceptive injectables, and oral contraceptive pills.

In 2012, the global contraceptives market was worth US$16.0 billion; however, presently, the market is expected to grow at a CAGR of 5.5% from 2013 to 2019. Among the varied contraceptive drugs, the oral contraceptive pills market held the highest revenue in 2012 and thus, led the overall contraceptives market in the same year. The growth was also mainly due to rising awareness about oral contraceptive pills among population through advertisements. People can buy drugs over-the-counter as well.

At the same time, the contraceptive devices market - male condoms was considered to be the largest market segment due to awareness among population and increased accessibility with ease of use.

We are currently offering a flat 15% discount on all purchases until end of the March 2015!

Likewise, the report also provides details about the infertility technologies market which is broadly analyzed with respect to types of treatment procedures and drugs. The types of infertility treatment methods studied in the report include zygote intrafallopian transfer (ZIFT), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF), and gamete intrafallopian transfer (GIFT). Furthermore, with respect to infertility drugs, the market witnesses three primary classes involving certain leading brands (by sales), namely, androgens, gonadotropins, and erectile dysfunction. Some of the other drugs analyzed in this study report include AndroGel, Viagra, Gonal-f, Cialis, Follistim AQ, Testim, and Levitra/Staxyn. 

Among all the aforementioned drugs, Viagra was the largest drug brand (by revenue) in 2012 and has been a renowned and approved brand by the U.S. FDA, since 1998. Owing to increasing incidences of erectile dysfunction in male infertility, Viagra is still at a commanding position in the global infertility market. Moreover, for testosterone deficiency, AndroGel is the most preferred drug for the treatment, and Gonal-f under the gonadotropin class is a widely prescribed brand to achieve better results for infertility issues. 

The report study observes some of the main players in the global human reproductive technologies market which include Merck Serono, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott Laboratories, Bayer AG, Watson Pharmaceuticals, Pfizer, Inc., and Reckitt Benckiser. Generic manufacturers such as Par Pharmaceuticals and Watson Pharmaceuticals are expected to penetrate the global human reproductive technologies market with their new generic versions by 2015. 

North America was a dominant player in the global human reproductive technologies market in 2012 and this region is further expected to maintain its market position till 2019. Nevertheless, the Asia-Pacific contraceptive technologies market is also growing rapidly mainly due to the rising awareness and acceptance of human reproductive technologies in this region. The growth rate is estimated to be 6.9% CAGR from 2013 to 2019.  

Browse Full Press Release

About Transparency Market Research
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453

Browse The Market Research Blog :